Literature DB >> 19565203

Apolipoprotein E polymorphism in hemodialyzed patients and healthy controls.

Jaroslav A Hubacek1, Silvie Bloudickova, Ruzena Kubinova, Hynek Pikhart, Ondrej Viklicky, Martin Bobak.   

Abstract

A possible association between end-stage renal disease (ESRD) and apolipoprotein E (APOE) polymorphism was found in some but not all studies. We have analyzed the APOE genotypes in 995 hemodialyzed patients (cases) and a sample of 6242 healthy individuals (controls) in the Czech Republic. There was a statistically significant difference in the frequency of APOE alleles between cases and controls, with more carriers of the APOE2 allele in ESRD patients (15.9%) than in controls (12.2%) (P = 0.005). The odds ratio of ESRD for the APOE2 allele, compared with APOE3E3 homozygotes, was 1.37 (95% confidence interval 1.13-1.67). The strength of the association increased with the time spent on hemodialysis: the odds ratio of all-cause ESRD in patients dialyzed for eight or more years was 1.27 (0.94-1.71), for 1-8 years 1.41 (1.09-1.81), and less than 1 year (nonsurvivors) 1.94 (0.88-4.18). This study suggests that the APOE2 allele is a possible genetic risk factor for all-cause ESRD in Caucasians.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19565203      PMCID: PMC3951864          DOI: 10.1007/s10528-009-9266-y

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  21 in total

1.  ESRD patients in 2001: global overview of patients, treatment modalities and development trends.

Authors:  Stefan Moeller; Simona Gioberge; Gail Brown
Journal:  Nephrol Dial Transplant       Date:  2002-12       Impact factor: 5.992

2.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

Review 4.  The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter.

Authors:  Roberto Pecoits-Filho; Bengt Lindholm; Peter Stenvinkel
Journal:  Nephrol Dial Transplant       Date:  2002       Impact factor: 5.992

5.  A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion.

Authors:  G Chen; L Paka; Y Kako; P Singhal; W Duan; S Pillarisetti
Journal:  J Biol Chem       Date:  2001-09-28       Impact factor: 5.157

6.  Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients.

Authors:  G Güz; F Nurhan Ozdemir; S Sezer; I Işiklar; Z Arat; M Turan; M Haberal
Journal:  Am J Kidney Dis       Date:  2000-10       Impact factor: 8.860

Review 7.  Progression of renal disease: new insights into risk factors and pathomechanisms.

Authors:  Marie-Luise Gross; Kerstin Amann
Journal:  Curr Opin Nephrol Hypertens       Date:  2004-05       Impact factor: 2.894

Review 8.  Apolipoprotein E polymorphism and atherosclerosis.

Authors:  J Davignon; R E Gregg; C F Sing
Journal:  Arteriosclerosis       Date:  1988 Jan-Feb

Review 9.  Apolipoprotein E and renal disease.

Authors:  Evagelos Liberopoulos; Kostas Siamopoulos; Moses Elisaf
Journal:  Am J Kidney Dis       Date:  2004-02       Impact factor: 8.860

10.  Ghrelin variants influence development of body mass index and plasma levels of total cholesterol in dialyzed patients.

Authors:  Jaroslav A Hubacek; Silvie Bloudícková; Romana Bohuslavová; Petr Táborský; Vladimír Polakovic; Magdaléna Sazamová; Eva Svítilová; Jicí Vlasák; Iva Sojková; Miroslav Ryba; Petr Knetl; Martin Ullrych; Radim Drahozal; Veronika Pavuková; Beata Pavlíková; Drahomíra Fischlová; Magdaléna Mokrejsová; Hana Chmelícková; Eva Pauchová; Pavel Vyskocil; Zuzana Nýdlová; Jaroslav Kopenec; Petr Fixa; Jan Hajný; Petr Bubenícek; Petr Syrovátka; Jana Zahálková; Stanislav Surel; Zdenek Hobzek; Ales Hrubý; Jana Suchanová; Svetlana Vanková; Jana Brabcová; Ondrej Viklický
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

View more
  5 in total

1.  Distribution and effect of apo E genotype on plasma lipid and apolipoprotein profiles in overweight/obese and nonobese Chinese subjects.

Authors:  Juan Zhang; Ping Fan; Rui Liu; Yi Huang; Shanshan Liang; Yu Liu; Yin Wu; Huai Bai
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

2.  APOE polymorphism is associated with lipid profile, but not with arterial stiffness in the general population.

Authors:  Rafael O Alvim; Silvia R S Freitas; Noely E Ferreira; Paulo C J L Santos; Roberto S Cunha; José G Mill; José E Krieger; Alexandre C Pereira
Journal:  Lipids Health Dis       Date:  2010-11-08       Impact factor: 3.876

3.  The APOE4 allele is associated with a decreased risk of retinopathy in type 2 diabetics.

Authors:  Lucie Dlouha; Terezie Pelikanova; Jiří Veleba; Vera Adamkova; Vera Lanska; Tomas Sosna; Lukas Pacal; Katerina Kankova; Jaroslav A Hubacek
Journal:  Mol Biol Rep       Date:  2021-07-30       Impact factor: 2.316

Review 4.  Apolipoprotein E gene variants on the risk of end stage renal disease.

Authors:  Cheng Xue; Wei Nie; Dan Tang; Lujiang Yi; Changlin Mei
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

5.  Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function.

Authors:  Mauro Sergio Martins Marrocos; Andrei Alkmin Teixeira; Beata Marie Quinto; Silmara de Melo Carmona; Mariana Kuniyoshi; Cassio Jose Rodrigues; Maria Aparecida Dalboni; Silvia Manfredi; Maria Eugênia Canziani; Marcelo Costa Batista
Journal:  Lipids Health Dis       Date:  2016-01-20       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.